Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Perflutren - Lantheus Medical Imaging

Drug Profile

Perflutren - Lantheus Medical Imaging

Alternative Names: Definity; Definity Vial; DMP 115; Luminity; MRX-115; Perflutren (PEG); Perflutren Lipid Microsphere; YM 454

Latest Information Update: 19 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImaRx Therapeutics
  • Developer Astellas Pharma; Lantheus Medical Imaging
  • Class Contrast media; Fluorocarbons
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders
  • Clinical Phase Unknown Kidney disorders; Liver disorders

Most Recent Events

  • 01 Oct 2018 Lantheus Medical Imaging initiates enrolment in a phase III BENEFIT1 trial for Cardiovascular disorders (Diagnosis) in USA (NCT03571672)
  • 24 Jun 2018 Biomarkers information updated
  • 02 May 2018 Clinical trials in Cardiovascular disorders (Diagnosis) in China (IV) before May 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top